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In this study, a panel of 39 primary malignant fibrous histiocytomas (MFH) of high malignancy grade were characterised for
chromosomal alterations. The results were then evaluated in relation to the survival and the occurrence of recurrent disease during
follow-up for an average period of 63 months. Chromosomal alterations detected by comparative genomic hybridisation (CGH)
were recorded in 37 of the 39 cases analysed. The most frequent CGH abnormalities were gains of 17p, 20q, 16p, 17q, 1p31, 7q21,
and 9cen-q22, and losses of 9p21-pter and 13q21–22. However, the patterns of CGH imbalances did not allow the identification of
a single common event, suggesting that the key initiating event(s) is not a numerical imbalance. Patients with tumours harbouring a
gain of 17q showed significantly longer overall and disease-free survival (P¼0.001 and 0.008) as well as lower frequency of metastasis
(P¼0.018) during follow-up. Taken together, the findings suggest that the clinical outcome of MFH is associated with the genetic
profiles of the primary tumours. Importantly, a subgroup of MFHs characterised by a low risk of developing metastasis and local
recurrence is recognised based on their frequent gains of 17q by CGH.
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Malignant fibrous histiocytoma (MFH) is a type of soft tissue
sarcoma (Enzinger and Weiss, 2001), typically showing a clinically
aggressive behaviour with frequent development of distant
metastases and local recurrences after surgery. Microscopically,
MFHs are recognised as pleomorphic tumours composed of
fibroblasts, myofibroblasts, and histiocytes (Enzinger and Weiss,
1995); however, the cellular origin is still unclear. So far, the
parameters size, localisation, necrosis, intravascular invasion,
and histopathological characteristics of the tumour have been
demonstrated to have prognostic value (Gustafson, 1994;
Scully et al, 1994; Singer et al, 1994; Tanabe et al, 1994;
Coindre et al, 1996; Le Doussal et al, 1996; Fletcher et al, 2001;
Gibbs et al, 2001). However, these parameters are not specific
and sensitive enough to allow the identification of a patient
group at high risk of developing metastases and local
recurrences. Therefore, the development of additional and
objective prognostic markers would be of obvious clinical value
in treatment planning.
The MFH entity is today regarded as a heterogenous group of
tumours, and from its initial introduction more than 20 years ago,
the relative frequency of soft tissue sarcomas diagnosed as MFH
has varied, both between clinical units and during time (Fletcher
et al, 2001). Hence, further elucidation of the genetic profiles of
tumours diagnosed as MFH are expected to contribute to the
improved understanding of aetiological and prognostic aspects of
this tumour group. Cytogenetic data on MFHs are so far limited,
and the reported karyotypes are often complex with multiple
numerical and structural abnormalities. No specific recurrent
chromosomal translocation has been identified so far in MFH, but
recurrent breakpoints in 1p36, 1q11, 1q21, 3p12, 11p11, 17p11, and
19p13 have been reported (Rydholm et al, 1990; Choong et al,
1996; Mertens et al, 1998). Additional chromosomal aberrations
have been identified in studies using comparative genomic
hybridisation (CGH) (Larramendy et al, 1997; Mairal et al, 1999;
Parente et al, 1999). The recurrent gains of chromosomal regions
1p31 and 7q32 were significantly associated with a poor overall
survival and poor metastasis-free or overall survival, respectively
(Larramendy et al, 1997). In agreement with the CGH findings of
12q gain, candidates within this chromosomal region, such as
sarcoma amplification sequence (SAS), human homologue of
murine double minutes 2 (MDM2), cyclin-dependent kinase 4
(CDK4), and high-mobility group protein IC (HMGIC) have been
shown to be amplified in MFH by molecular analyses (Nilbert et al,
1995). More recently, an amplicon derived from 8p23.1 was found
to be amplified and overexpressed in MFHs, and from this area a
candidate gene designated MASL1 was subsequently isolated
(Sakabe et al, 1999). Frequently lost regions including 9p21 and
13q14-q21 pinpointed the candidates p16
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s(13q14), which were subsequently shown to be deleted by
molecular approaches (Simons et al, 2000).
Here, a series of primary MFH cases of high malignancy grade
were characterised genetically, and the findings were then
evaluated in relation to the clinical outcome regarding survival
and development of recurrent disease during follow-up.
MATERIALS AND METHODS
Patients and tumour samples
The study includes 39 MFH cases identified from all patients
treated for a primary soft tissue sarcoma of high malignancy
grade at the Karolinska Hospital between 1986 and 1993 (A ˚hle ´n
et al, in preparation). All patients were retrospectively followed
up until October 2001 or until the patient’s death (mean 63;
range 3–134 months), and the occurrence of metastasis and/or
local recurrence was recorded. None of the patients had
received preoperative or postoperative chemotherapy or radiation
treatments, none was diagnosed with local or distant metastases at
the time of the initial surgery, and none died from intercurrent
disease within 3 years after the diagnosis. The diagnosis of MFH
was established at histopathological re-evaluation of paraffin
sections stained with haematoxylin and eosin by one of the
authors. The classification followed the published criteria
(Enzinger and Weiss, 1995), and was based on the exclusion of
other types of sarcomas in combination with the recognition
of a heterogeneous morphology typical of MFH with characteristic
myxoid, pleomorphic or storiform growth pattern or the presence
of giant cells. When necessary, the differential diagnostics to
other types of soft tissue sarcomas were supported by the
results from immunostainings according to the published recom-
mendations (Weiss, 1994; Enzinger and Weiss, 1995). All cases
were classified as being of high-malignancy grade, that is, grade 3
or 4 on a four-graded scale and which is based on the estimation of
cellularity, cellular atypia, necrosis, and mitotic frequency
(Angervall et al, 1986).
DNA extractions
DNA was extracted from the 39 frozen tumour samples obtained
at surgery and stored at  701C. At the time of the initial collection,
a representative imprint was performed from each case and
stained with Feulgen. Re-evaluation of these slides confirmed
that the tumours contained a clear majority of tumour cells
(470%), and were therefore suitable for CGH analysis. From
each of these frozen samples, five 8mm consecutive sections
were cut and used for DNA extraction using the QIA amp DNA
Mini Kit (QIAGEN, Hiden, Germany) according to the procedure
suggested by the manufacturer. For 10 of the cases, DNA was also
extracted from sections of the paraffin blocks used for the
histopathological re-evaluation.
Comparative genomic hybridisation
Comparative genomic hybridisation was performed on DNA
extracted from the 39 frozen MFH tumours, and for 20 of the
tumours the experiments were performed in duplicate with
identical results. As an external control for the tumour samples,
DNAs from corresponding paraffin blocks were analysed in
parallel for 10 of the cases, which always gave the same results.
In control experiments, normal male DNA was hybridised against
normal female DNA, and as a negative control DNA from
histopathologically normal tissue adjacent to a tumour was
Table 1 Summary of clinical data of the 39 cases of MFH in the study
Recurrent disease End of follow-up 5-year survival
Informative Rec/Met DF DOD NED DFS mean DFS OAS
Variable (n¼)( n¼)( n¼)( n¼)( n¼) (months) (%) (%)
Sex
Female 20 13 7 11 9 36 37 55
Male 19 10 9 8 11 45 45 55
Malignancy grade
Grade III 14 10 4 6 8 35 34 59
Grade IV 25 13 12 13 12 40 44 50
Depth
Intramuscular 15 10 5 9 6 32 32 43
Subcutaneous 9 2 7 0 9 — 66 70
Extracompartmental 12 8 4 7 5 33 23 43
Size (cm)
48 19 15 4 13 6 24 18 36
p8 19 7 12 5 14 — 66 72
Surgical margin
Wide 18 10 8 7 11 46 43 58
Marginal 10 4 6 3 7 — 57 65
Intralesional 7 5 2 5 2 26 14 29
Site
Upper extremity 3 2 1 1 2 — 17 19
Lower extremity 24 14 10 12 12 36 38 58
Trunk 7 4 3 4 3 16 23 32
Pelvis 5 3 2 2 3 — 19 24
Age at diagnosis (years)
460 26 13 13 11 15 69 52 60
p60 13 10 3 8 5 16 23 43
Total 39 23 16 19 20 40 43 56
DF¼disease free; DOD¼dead of disease; NED¼no evidence of disease; DFS¼disease-free survival; OAS¼overall survival.
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shybridised. Comparative genomic hybridisation was performed
essentially as described (Kallioniemi et al, 1994). In short, genomic
tumour DNAs were directly labelled by nick-translation using
fluorescence isothiocyanate 12-dUTP (DuPont NEN, Boston,
MA, USA). The nick-translation conditions were adjusted
to obtain DNA fragments ranging from 300 to 2000bp. Spectrum
Red labelled normal reference DNA (Vysis Inc., Downers
Grove, IL, USA) was used as control DNA. The tumour DNA,
normal reference DNA, and unlabelled Cot-1 DNA (Life Technol-
ogies, Gaithersburg, MD, USA) were mixed with 10mlo f
hybridisation solution (50% formamide, 10% dextran sulphate
in 2 SSC), denatured, and applied onto denatured normal
metaphase slides (Vysis Inc.). Hybridisation was performed
at 371C for 48–72h, following which the slides were washed,
dried, and counterstained with 0.1mg/ml 4,6-diamidino-2-pheny-
lindole (DAPI, Sigma Inc.) in an anti-fade solution (Vectashield,
Vector Inc.).
Digital image analyses
In all, 10 three-colour digital images (DAPI, FITC, and Spectrum
Red fluorescence) were captured from each experiment using a
Zeiss Axioplan 2 imaging (Carl Zeiss Jena GmbH, Jena, Germany)
epifluorescence microscope and analysed with the isis/CGH
software (Metasystems). For each tumour DNA hybridisation, at
least 12 ratio profiles were averaged for each chromosome to
reduce noise. The chromosomal regions were interpreted
as lost when the green-to-red ratio was less than 0.75, and as
gained if the ratio was greater than 1.25. A high-level amplification
was defined if the ratio exceeded 2.0. The analyses of the profiles
observed in 1p and 16p were interpreted with caution, in
particular, for the low level of imbalances. Heterochromatic
regions, the short arm of the acrocentric chromosomes, chromo-
some Y, and the GC-rich chromosome regions 19 and 22q known
to give some false-positive results, were excluded from the
evaluation.
Statistical analyses
Correlations between the total number of CGH alterations, as well
as the most common alterations of individual chromosomes
were evaluated in relation to the outcome during follow-up using
Figure 1 CGH profiles demonstrating tumours with (A–D) and
without (E and F) copy number gains including chromosome 17q in
MFH tumours.
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Figure 2 A summary of DNA sequence number alterations detected by CGH in at least two of the 39 MFH tumours studied as shown at the top. One
alteration identified in one tumour is represented by one line, with losses indicated to the left and gains to the right of the ideograms. High-level
amplifications of subchromosomal regions are marked with thick lines. The distribution of the CGH alterations detected in MFH tumours for the most
frequently involved subchromosomal regions are illustrated at the bottom. Red boxes indicate a gain in one tumour, while black boxes represent tumours
without a CGH imbalance in the particular region. The cases are ordered 1–39 from left to right, and the patients who developed distant metastases and/or
local recurrences during follow-up are marked by M and R, respectively.
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sthe Kaplan–Meier survival test and the log rank test. The
comparisons were made against patients who were without
evidence of disease at the end of follow-up. To evaluate if the
significant CGH changes were independent of the already known
prognostic parameters of tumour size, tumour depth, and high
mitotic index, necroses multivariate analyses with Cox regression
analyses were used. Owing to the limited number of cases analysed,
the different variables were compared in pairs in the multivariate
analyses. The calculations were performed in Statistica 6.0
Software, and probabilities of less than 0.05 were accepted as
significant.
RESULTS
In this study, a series of 39 primary MFH tumors (Table 1) were
screened for genomic imbalances using CGH. The clinical data for
the cases studied are summarised in Table 1. Of the 39 cases, 20
Table 2 The most frequent CGH alterations in relation to the total number of alterations detected in the 39 MFH
No. of
Gain involving chromosomal regions
Case no changes 20q 17p 7q21 1p31 1q23–24 17q 9cen-q22 16p Other gains Other losses
10
20
3 1 20q
4 1 17p
51 17p
6 1 12p
71 4 p
81 7 q
91 4q
10 1 1q41-qter
11 1 20p
12 1 12q14–15
13 1 1p31–q24 1p31–q24
14 2 20q 10p
15 2 17p 17q Xp
16 2 9cen-q22 Xq,
17 2 7cen-q31 16p
18 2 1p32–34 9p13-pter
19 2 20q 17q
20 3 17p 9q 15q24-qter
21 3 11, 14q, 16q
22 4 20q 17p 12q12–15 9p
23 4 20q 16p 7p X
24 5 11cen-q13 4, 5q14–q23, 13q14–32 , 6q14–q16
25 5 20q 17p 1p31-pter 1q11–24 17q 5p,12q23-qter,
18p
26 5 17p 1p31-pter 17q 16p 9q34-qter,
11cen-q13
27 6 20q 17q 9q 16p 6p 13q
28 7 17p 9q 8q21.1–q22, 12q11–15, 8p21-pter, 20p
29 7 17p 7cen-q21 17q 16p 2p22-pter, 6p, 7p,
9q33-qter
13q12–31
30 7 17p 1q23–32 17q 16 6p24–26, 6q24-26,
12q13–21
9p
31 8 17p 7q11.1-21 16p 10p, 11cen-q13,
13q14-qter, Xpter-q21
8q22-qter
32 8 17p 1p31-pter 17q 9q 16p 6q22–24, 13q31-qter,
18p
8,
33 9 20q 17p 7q 17q 9q 6p21.3-pter,
6q24-qter, 7p, 15q, 18p
3q
34 9 20q 17q 4p15.3-pter, 5p,
10p, 11cen-q13
3q, 6q11–21,
9p21-pter
35 11 20q 17p 7q 1p31-pter 17q 16p 7p, 11p14-q13,
18p
4, 6q, 10,
13q14-qter
36 11 20q 7q21–32 1cen-p31 9cen-q22 16p 4q13–24, 11cen-q13 1q21-qter, 9p, 13q,
11q22-qter
37 12 20q 17p 7cen-q21 1p31-pter 1q23–25 9q 16p 7p, 8p11.2–12, 11cen-q14, Xp,
13q22-qter, 19q12–13.2
38 15 20q 17p 1p21-pter 1cen-q32 17q 16p 2q12.2–21, 6p21.1–21.3,
6q24-qter8p,
15q, 18, Xp
4q21-qter, 6q12–22,
11q21-qter
39 16 20q 17p 7cen-q32 1p 1cen-q31 9q 2p13–q21, 3q,
5p, 6, 8q24.1-qter,12q,
21q, Xp
2q33-qter, 3p23-pter,
10q23-qter
Bold letter represents high-level amplification.
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swere female and 19 were male, and the median age at the initial
surgery was 69 years (range 22–82). All patients had been
surgically treated and the tumours were removed with the best
possible margin. The patients were retrospectively followed up,
during which recurrent disease in the form of local recurrence and/
or distant metastases were recorded in 23 patients. At the end of
follow-up, 19 patients had died from the disease, while 20 were
without evidence of the disease.
The CGH alterations detected in the individual tumours are
detailed in Table 2. An example of the obtained CGH profiles is
shown in Figure 1, and the subchromosomal regions involved are
illustrated in Figure 2. Overall, genetic imbalances were found in
all chromosomes analysed, and gains were more frequently
detected than losses. Gains were commonly found at chromosomal
regions 17p (17 out of 39), 20q (14 out of 39), 16p and 17q (12 out
of 39), 1p31, 7q21, and 9cen-q22 (9 out of 39) (Figure 2, Table 2).
In addition, high copy number gains were observed in three
tumours, each involving a different subchromosomal region, that
is 1q23–32, 7q21–32, and Xp (Figure 2, Table 2). Losses were most
frequently detected in the subchromosomal regions 9p21-pter and
13q21–22 (five out of 39) in this series (Figure 2, Table 2). Some
alterations were found to occur as single alterations, while others
were only recognized in tumours with several other changes.
However, the patterns of CGH imbalances did not allow the
identification of a single common event.
Of the 39 tumors analysed, 37 displayed at least one CGH
alteration and the number of detected changes varied from 1 to 16
in the individual tumours. When compared to the sizes of the
tumours, no association to the total number of CGH alterations
was observed. The total numbers of CGH alterations as well as the
most commonly involved subregions (16p, 17q, 1p31, 7q21, 9cen-
q22, 17p, and 20q) were then evaluated in relation to the survival
and the development of metastases only or in combination with
local recurrence during follow-up. From these comparisons,
several interesting associations were revealed. We found that
cases with four or more alterations were significantly associated
with longer overall (P¼0.07) and disease-free survival (P¼0.018),
and with lower frequency of metastases only (P¼0.009) or in
combination with local recurrence (P¼0.036) during follow-up.
Most significantly, gain of 17q was strongly associated with longer
overall survival (P¼0.001) and disease-free survival (P¼0.004,
Figure 3), as well as with a lower frequency of metastases only
(P¼0.018, Figure 3) or in combination with local recurrence
(P¼0.01) during follow-up. Following the identification of 17q
gain as significantly associated with prognosis in univariate
analyses, multivariate analyses was used to demonstrate that gain
of 17q is independent of other known prognostic factors including
tumour size, tumour site, and mitotic index (P-values between 0.01
and 0.04).
DISCUSSION
Gross chromosomal alterations leading to numerical imbalances
were shown to be present in the vast majority of MFH. Some
alterations were found to occur as a single alteration, while others
were only recognised in tumours with several other changes.
However, neither in the tumours with few nor in tumours with
multiple changes did the individual CGH profiles allow the
identification of a single common event. This implies that
alterations beyond the detection level of CGH are important for
early tumorigenesis, such as translocations, inversions or other
balanced alterations. As illustrated in Figure 2, several chromoso-
mal regions tended to be altered together in the same tumour,
possibly reflecting a functional relationship between the alterations
or a genetic heterogeneity of the MFH entity or both.
MFH tumours are generally of high malignancy grade (i.e. 3 or 4
on a four-graded scale), and the survival rate varies from 50 to 70%
(Rooser et al, 1991; Pritchard et al, 1993; Le Doussal et al, 1996).
However, for patients with metastatic or recurrent disease, the
expected survival is very poor (Enzinger and Weiss, 2001).
Therefore, the recognition of patients with tumours diagnosed as
highly malignant MFH, and which are at risk of developing
metastasis and local recurrence, is essential for their proper
clinical handling and treatment. At best, this distinction of a high-
risk group should be performed by the analyses of markers on
tumour specimens from the primary surgery, and using a robust
and reproducible methodology. The observation that the different
types of CGH profiles for primary MFH tumours were associated
with the clinical outcome of the MFH disease during follow-up
represents a first step towards these goals. Specifically, we found
that patients with gain of 17q in their tumours had significantly
improved disease-free survival, and rarely developed metastases
during follow-up (Figure 3). Although the findings are statistically
significant, they were based on a limited number of cases, and
should therefore be confirmed in a larger sample series.
In this study, we have chosen to evaluate the CGH imbalances in
relation to the survival and the development of metastases only or
in combination with local recurrence. The development of local
recurrence only would be another highly relevant parameter of the
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Figure 3 Kaplan–Meier curves demonstrating the significant associations
between gain of 17q and longer disease-free survival (A), and a lower
frequency of metastasis without local recurrence (B), during follow-up of
patients with highly malignant MFH tumours. The comparisons were made
against cases who were without evidence of the disease at the end of
follow-up.
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sclinical outcome. However, since the extent of the surgical margin
should optimally be taken into account in the evaluations, a larger
series of MFH cases would be required to allow separate analyses
of patients with wide, marginal, and intralesional excision. Given
these uncertainties, it can still be noted that gain of 17q and 16p
were both associated with a lower occurrence of local recurrence
only during follow-up (P¼0.011 and 0.030, respectively). Simi-
larly, cases with gain of 16p, 17p, and 20 developed significantly
lower frequencies of metastases in combination with local
recurrences (P¼0.02, 0.048, and 0.020, respectively).
For several types of sarcomas, the detailed elucidation of genetic
changes in primary tumours have identified alterations associated
with the outcome during follow-up (Ladanyi et al, 2002; Mertens
et al, 2002). The findings in this study demonstrate that the clinical
outcome for patients with highly malignant MFH is associated with
the genetic profiles of the primary tumours. On a purely
speculative basis, we could consider that one MFH subgroup
would be genetically characterised by gain of 17q, and clinically by
a less aggressive course with a low risk of metastases and local
recurrences, and hence a better survival. The second subgroup
would be clinically characterised by an aggressive course with
frequent development of distant metastases and local recurrences.
The lack of recurrent genetic abnormality by CGH in this latter
group would then imply a structural abnormality in the aetiology.
In further support of this hypothesis, recurrent structural
alterations involving chromosomes 1, 3, 11, 17, and 19 have been
reported in MFH, some of which have been associated with a high
risk of recurrence and metastases (Rydholm et al, 1990; Choong
et al, 1996; Mertens et al, 1998). Finally, an alternative, but less
likely, explanation would be that the high- and low-risk groups
could have common unidentified initiating genetic events, and that
the varying clinical course results from secondary chromosomal
imbalances such as gain of 17q in the low-risk group. Regardless of
the mechanism involved, detailed elucidation of the structural
abnormalities in cultured MFH tumours would be worthwhile
to proceed using a molecular cytogenetic approach. Furthermore,
it is envisaged that the exact identification of the putative
oncogene activation driving the 17q gain will be valuable for
genetic dissection of the MFH entity, and in addition will enable
the development of additional prognostic markers for clinical
practice.
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